Effectiveness and Safety of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: A Multicenter, Retrospective Real-World Study in China.

Clin Med Insights Oncol · 2026 · PMC12820020 · PMID 41574052

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

did not reach statistical significanceP = .059so close (0.05 < p ≤ 0.1)

Although the median PFS of patients receiving Atezo + Bev as first-line treatment was extended compared to those receiving Atezo + Bev as second-line treatment, the difference did not reach statistical significance ( P = .059) ( Figure 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.